**Efficacy and safety of intravenous** **belimumab in Japanese patients with systemic lupus erythematosus: a subgroup analysis of a Phase 3 randomized placebo-controlled trial**

Yoshiya Tanaka, Damon Bass, Myron Chu, Sally Egginton, Beulah Ji, Herbert Struemper, David Roth

 **Supplementary Tables**

**Supplementary Table 1. Duration of Week 52 SRI response by montha (mITT population)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Intervalb, n (%)** | **Placebo****(n=21)** | **Belimumab 10 mg/kg (n=39)** | **p-valuec** |
| n | 20 | 39 |  |
| ≥1 month | 4 (20.0) | 16 (41.0) | 0.1490 |
| ≥2 months | 4 (20.0) | 15 (38.5) | 0.2392 |
| ≥3 months | 3 (15.0) | 15 (38.5) | 0.0793 |
| ≥4 months | 3 (15.0) | 13 (33.3) | 0.2161 |
| ≥5 months | 3 (15.0) | 12 (30.8) | 0.2240 |
| ≥6 months | 3 (15.0) | 12 (30.8) | 0.2240 |
| ≥7 months | 3 (15.0) | 10 (25.6) | 0.5106 |
| ≥8 months | 3 (15.0) | 9 (23.1) | 0.7337 |
| ≥9 months | 3 (15.0) | 8 (20.5) | 0.7337 |
| ≥10 months | 2 (10.0) | 6 (15.4) | 0.7040 |
| ≥11 months | 2 (10.0) | 4 (10.3) | >0.9999 |

aPatients are included in multiple categories. A month is defined as 30 days. For patients without any response at Week 52 and for patients who take a protocol-prohibited medication, the duration of response was set at 0 days; btime period prior to Week 52 response; cFisher's exact test

mITT, modified intent-to-treat; SRI, SLE Responder Index.

Supplementary Table 2. BILAG improvementa (by organ domain) from baseline to Week 52 among patients with an A or B score at baseline

|  |  |  |  |
| --- | --- | --- | --- |
| **Organ domain**  | **Placebo****(n=21)** | **Belimumab 10 mg/kg (n=39)** | **p-valueb** |
| Mucocutaneous |  |  |  |
| A or B score at baseline, n | 11 | 26 |  |
| Improvement at Week 52, n (%) | 2 (18.2) | 15 (57.7) | 0.0365 |
| Musculoskeletal |  |  |  |
| A or B score at baseline, n | 12 | 22 |  |
| Improvement at Week 52, n (%) | 4 (33.3) | 13 (59.1) | 0.2818 |
| Renal |  |  |  |
| A or B score at baseline, n | 5 | 5 |  |
| Improvement at Week 52, n (%) | 2 (40.0) | 3 (60.0) | >0.9999 |
| Vascular |  |  |  |
| A or B score at baseline, n | 2 | 8 |  |
| Improvement at Week 52, n (%) | 0 | 5 (62.5) | 0.4444 |
| Hematology |  |  |  |
| A or B score at baseline, n | 4 | 2 |  |
| Improvement at Week 52, n (%) | 0 | 0 | NC |
| General |  |  |  |
| A or B score at baseline, n | 1 | 4 |  |
| Improvement at Week 52, n (%) | 0 | 4 (100.0) | 0.2000 |
| Neurological |  |  |  |
| A or B score at baseline, n | 0 | 0 |  |
| Improvement at Week 52, n (%) | 0 | 0 | NC |
| Cardiovascular and respiratory |  |  |  |
| A or B score at baseline, n | 0 | 0 |  |
| Improvement at Week 52, n (%) | 0 | 0 | NC |

aPatients with an A at baseline who changed to a B, C, or D or patients with a B at baseline who changed to a C or D were considered to have improvement; bFisher's exact test.

BILAG, British Isles Lupus Assessment Group; NC, not calculable.